It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim Constantino. Medicare Part D plans can cover obesity drugs if they are used for an additional medically accepted purpose approved ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

Monday’s latest is the FDA issued a notice in the Federal Register that determined 35 food contact notifications (FCNs) related to per- and polyfluoroalkyl substances (PFAS) are no longer effective.